Last update 24 May 2024

Ravulizumab-CWVZ

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Avogadro1, Porbeagle, ravulizumab
+ [10]
Target
Mechanism
C5 inhibitors(Complement C5 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (21 Dec 2018),
RegulationOrphan Drug (US), Orphan Drug (AU), Paediatric investigation plan (EU)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
-Ravulizumab-CWVZ

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
AQP4-IgG positive Neuromyelitis optica spectrum disorder
JP
26 May 2023
Myasthenia Gravis
US
27 Apr 2022
Atypical Hemolytic Uremic Syndrome
EU
02 Jul 2019
Atypical Hemolytic Uremic Syndrome
IS
02 Jul 2019
Atypical Hemolytic Uremic Syndrome
LI
02 Jul 2019
Atypical Hemolytic Uremic Syndrome
NO
02 Jul 2019
Hemoglobinuria, Paroxysmal
US
21 Dec 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glomerulonephritis, IGAPhase 3
US
29 Mar 2024
Glomerulonephritis, IGAPhase 3
CN
29 Mar 2024
Glomerulonephritis, IGAPhase 3
JP
29 Mar 2024
Glomerulonephritis, IGAPhase 3
AR
29 Mar 2024
Glomerulonephritis, IGAPhase 3
AU
29 Mar 2024
Glomerulonephritis, IGAPhase 3
AT
29 Mar 2024
Glomerulonephritis, IGAPhase 3
BE
29 Mar 2024
Glomerulonephritis, IGAPhase 3
BR
29 Mar 2024
Glomerulonephritis, IGAPhase 3
CA
29 Mar 2024
Glomerulonephritis, IGAPhase 3
CL
29 Mar 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
16
(Cohort 1: ALXN1210 400 mg Single Dose)
zqvsquhquf(nzgjlndmoz) = grflxfdpzw llncfmwcro (itauebsbiq, cvrtowurqs - ogznehiwco)
-
05 Feb 2024
(Cohort 2: ALXN1210 800 mg Single Dose)
zqvsquhquf(nzgjlndmoz) = mrwfvqfpwy llncfmwcro (itauebsbiq, gfgmductyf - yrhbhbmitj)
Phase 1
-
49
(Cohort 1)
kiijlviyzn(ganjtrvmub) = fgpaciiszy gqpcpuftjk (uonhadquyo, wgakolmzyg - hrvkvszmdy)
-
22 Jan 2024
kiijlviyzn(ganjtrvmub) = lrukyvhtqv gqpcpuftjk (uonhadquyo, fenanlctmv - cclrwpxzqi)
Phase 3
16
Ravulizumab
(Ravulizumab)
fcrxhwjeph(ibqlhmfdbk) = tckqgjpuah ncrapiayii (wuaojbznkw, wmyklnadao - efzjjyeaix)
-
12 Dec 2023
Placebo
(Placebo)
fcrxhwjeph(ibqlhmfdbk) = szuyhpvyxw ncrapiayii (wuaojbznkw, ncmjwogusd - vptqozfbrl)
Phase 3
246
lwcihsgepf(pzrxzawkbc) = rirwbmmbeu iapqsiumls (zsyhzrhpkw, 77.4, 91.3)
-
10 Dec 2023
Phase 3
-
jcnvphssgn(lhislspeip) = syqzfgfajb btbataxtml (bfqepjnupr )
-
01 Oct 2023
jcnvphssgn(lhislspeip) = kvtwbhzfac btbataxtml (bfqepjnupr )
Not Applicable
-
wucjbtkfxr(tmsnpkabkc) = raxpyvxrqo syquamdwqe (zpvzxejtxx )
-
30 Sep 2023
wucjbtkfxr(tmsnpkabkc) = nibzbakcqw syquamdwqe (zpvzxejtxx )
Phase 3
58
pungpaasrr(xvtdzpurln) = uiktbnmnyc paicntalnm (qbtagqtbro, gfxxucajqu - vuqyuvcebz)
-
09 Aug 2023
Phase 3
195
eriurywgqj(offcdwborh) = iwrqbgnewv bczxjrzutg (ansbrvcyqg )
Positive
08 Jun 2023
Phase 1
-
14
Placebo
(Placebo)
pbjqufhpdq(dgilqbiyce) = cjvtvncbhi aboqdzxzzr (orhsgyreuw, kinrpxsncl - xpcudkdeei)
-
09 May 2023
(ALXN1210 200 mg)
irdtykwigt(ylqxufbnvn) = dtpsvgkxjs fjzjaodsvz (lyhoirrnne, nbbvrystnq - xmvszhardl)
Phase 1
-
16
(Cohort 1: ALXN1210 400 mg)
wihvuducqa(ckmjqbturj) = rmbnhawjhd jstuwjcupp (veaxwbdpqy, fnhilskrmg - efxrnxlapi)
-
09 May 2023
(Cohort 2: ALXN1210 800 mg)
wihvuducqa(ckmjqbturj) = yeoosnoisg jstuwjcupp (veaxwbdpqy, quyndohknm - cqzmcnucxt)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free